Solstein Capital’s Larimar Therapeutics LRMR Stock Holding History

Solstein Capital’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.7K	Hold	4,477	–	–	﹤0.01%	318
2026 Q1	$20.1K	Hold	4,477	–	–	0.01%	301
2025 Q4	$17.1K	Hold	4,477	–	–	0.01%	288
2025 Q3	$14.5K	Hold	4,477	–	–	﹤0.01%	304
2025 Q2	$12.9K	Hold	4,477	–	–	0.01%	319
2025 Q1	$9.63K	Hold	4,477	–	–	0.01%	239
2024 Q4	$17.3K	Hold	4,477	–	–	0.01%	214
2024 Q3	$29.3K	Hold	4,477	–	–	0.02%	179
2024 Q2	$32.5K	Hold	4,477	–	–	0.02%	164
2024 Q1	$34K	Hold	4,477	–	–	0.02%	161
2023 Q4	$20.4K	Hold	4,477	–	–	0.02%	186
2023 Q3	$17.7K	Hold	4,477	–	–	0.02%	190
2023 Q2	$14K	Hold	4,477	–	–	0.01%	205
2023 Q1	$20.3K	Hold	4,477	–	–	0.02%	164
2022 Q4	$18.5K	Hold	4,477	–	–	0.02%	180
2022 Q3	$14K	Hold	4,477	–	–	0.01%	211
2022 Q2	$9K	Hold	4,477	–	–	0.01%	263
2022 Q1	$18K	Hold	4,477	–	–	0.01%	257
2021 Q4	$48K	Hold	4,477	–	–	0.03%	218
2021 Q3	$52K	Hold	4,477	–	–	0.03%	228
2021 Q2	$44K	Hold	4,477	–	–	0.05%	228
2021 Q1	$65K	Buy	+4,477	New	+$81.3K	0.09%	192

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Solstein Capital's LRMR Position: Q2 2026 in Review

Solstein Capital held its Larimar Therapeutics (LRMR) position steady in Q2 2026 at 4,477 shares worth $13.7K. The position accounts for ﹤0.01% of the portfolio, ranked #318.

Solstein Capital first reported a position in LRMR in Q1 2021 and has held it in 22 quarters since. The position peaked at $65K in Q1 2021. 162 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

Solstein Capital held 4,477 shares of Larimar Therapeutics worth $13.7K as of Q2 2026.
Solstein Capital left its Larimar Therapeutics share count unchanged in Q2 2026.
Larimar Therapeutics made up ﹤0.01% of Solstein Capital's portfolio in Q2 2026, its #318 holding.
Solstein Capital first reported a position in Larimar Therapeutics in Q1 2021 and has held it in 22 quarters since.
Solstein Capital's Larimar Therapeutics position peaked at $65K in Q1 2021.
162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Solstein Capital's 13F filing for Q2 2026, filed 13 Aug 2026.